The study was done by researchers from Zion Medical, an Israeli biotech company, and the Hebrew University of Jerusalem. APOPTOSISThe study was done by researchers from Zion Medical, an Israeli biotech company, and the Hebrew University of Jerusalem. In the second part of the trial done two weeks later, patients were given the drug with additional retroviral treatment after four to five weeks. During the 10-week study, patients in both groups showed a significant increase in T-cell count — another name for CD4 cells, which play a role in the body’s immune system. ENZYMEThe drug is derived from HIV enzyme integrate that is responsible for inserting the virus’s genetic material into the DNA of the infected cell.

Source: Daily Nation November 05, 2018 03:11 UTC